BNT162b2 and ChAdOx1 nCoV-19 vaccine effectiveness against death from the delta variant

Aziz Sheikh; Chris Robertson; Bob Taylor

doi:10.1056/nejmc2113864

BNT162b2 and ChAdOx1 nCoV-19 vaccine effectiveness against death from the delta variant

Aziz Sheikh, Chris Robertson, Bob Taylor

Research output: Contribution to journal › Letter

83 Citations (Scopus)

Abstract

We recently reported vaccine effectiveness for the BNT162b2 vaccine (Pfizer–BioNTech) and the ChAdOx1 nCoV-19 vaccine (AstraZeneca) against infection and hospitalization caused by the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Scotland.1 At that time, the number of deaths was too small to allow estimation of vaccine effectiveness against death from infection with the delta variant.

Original language	English
Pages (from-to)	2195-2197
Number of pages	3
Journal	New England Journal of Medicine
Volume	385
Issue number	23
Early online date	20 Oct 2021
DOIs	https://doi.org/10.1056/nejmc2113864
Publication status	Published - 2 Dec 2021

Keywords

vaccine effectiveness
delta variant
COVID-19

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1056/nejmc2113864

Cite this

@article{1861e22c3b514b07bbf767d0f585b266,

title = "BNT162b2 and ChAdOx1 nCoV-19 vaccine effectiveness against death from the delta variant",

abstract = "We recently reported vaccine effectiveness for the BNT162b2 vaccine (Pfizer–BioNTech) and the ChAdOx1 nCoV-19 vaccine (AstraZeneca) against infection and hospitalization caused by the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Scotland.1 At that time, the number of deaths was too small to allow estimation of vaccine effectiveness against death from infection with the delta variant.",

keywords = "vaccine effectiveness, delta variant, COVID-19",

author = "Aziz Sheikh and Chris Robertson and Bob Taylor",

year = "2021",

month = dec,

day = "2",

doi = "10.1056/nejmc2113864",

language = "English",

volume = "385",

pages = "2195--2197",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "23",

}

TY - JOUR

T1 - BNT162b2 and ChAdOx1 nCoV-19 vaccine effectiveness against death from the delta variant

AU - Sheikh, Aziz

AU - Robertson, Chris

AU - Taylor, Bob

PY - 2021/12/2

Y1 - 2021/12/2

N2 - We recently reported vaccine effectiveness for the BNT162b2 vaccine (Pfizer–BioNTech) and the ChAdOx1 nCoV-19 vaccine (AstraZeneca) against infection and hospitalization caused by the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Scotland.1 At that time, the number of deaths was too small to allow estimation of vaccine effectiveness against death from infection with the delta variant.

AB - We recently reported vaccine effectiveness for the BNT162b2 vaccine (Pfizer–BioNTech) and the ChAdOx1 nCoV-19 vaccine (AstraZeneca) against infection and hospitalization caused by the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Scotland.1 At that time, the number of deaths was too small to allow estimation of vaccine effectiveness against death from infection with the delta variant.

KW - vaccine effectiveness

KW - delta variant

KW - COVID-19

U2 - 10.1056/nejmc2113864

DO - 10.1056/nejmc2113864

M3 - Letter

SN - 0028-4793

VL - 385

SP - 2195

EP - 2197

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 23

ER -

BNT162b2 and ChAdOx1 nCoV-19 vaccine effectiveness against death from the delta variant

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this